EGFR inhibitor could provide major advance in lung cancer
Results from AstraZeneca’s LAURA Phase III trial “represent a major…
Results from AstraZeneca’s LAURA Phase III trial “represent a major advance for [certain] patients with Stage III EGFR-mutated lung cancer".